News
Gedea Biotech strengthens IP portfolio with new European patent for treating infections with GDL
Gedea Biotech today announced that European patent no. 3 691 625 has entered into force, further strengthening Gedea’s…
Gedea Biotech strengthens IP portfolio with new US patent for vaginal formulation
Gedea Biotech today announced that the company has been granted a US patent for its vaginal formulation (patent no.…
Gedea Biotech appoints Julie Waras Brogren as new CEO to lead the company into its commercialization phase
Gedea Biotech today announces a planned CEO transition. After close to ten years as CEO, Annette Säfholm has decided to…
Gedea Biotech announce start of the clinical study BV2025 following CE marking of pHyph —first patients enrolled
Gedea Biotech today announced that the clinical trial BV2025 has started, following approval from the Swedish Medical…
Gedea Biotech strengthens its Board with extensive commercial expertise to support next phase
Lund, Sweden – November 18, 2025 Gedea Biotech, an innovative Swedish life science company in women’s health, today…
New insights into the vaginal microbiome: Emilia Lahtinen’s industrial PhD journey
At the intersection of academic research and biotech innovation, Emilia Lahtinen is pursuing her industrial PhD as a…
Gedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial Vaginosis
Gedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial Vaginosis
PRESS RELEASE Gedea Biotech Receives US Patent for Preventing Preterm Birth
Gedea Biotech announced today that the United States Patent and Trademark Office (USPTO) has granted the company’s…
Convincing efficacy and safety results
pHyph shows convincing symptom relief and longterm effect. Already at first day of treatment many patients see a relief in symptoms and at day 7 nearly 70% report absence of symptoms. When treated, the patients stay well and after 35 days, 100% of patients are still free from BV, compared to 54-77% with antibiotics.
90% Symptom reduction
In our most recent and largest clinical trial so far, symptom reduction was seen in 90% of patients.
Day 7
By day 7, nearly 70% of patients were free of symptoms.
Day 35
100% are still free from BV
The CE-mark confirms the efficacy and safety of our product, and opens up a large market opportunity in Europe. The novel, antibiotic free mode of action will improve treatment of bacterial vaginosis for millions of women and reduce use of antibiotics, and our ambition is to make pHyph available in pharmacies in the first markets in 2026
Annette Säfholm, CEO
annette.safholm@gedeabiotech.com
+46 (0) 708 - 91 86 81
According to the World Health Organization (WHO), antibiotic resistance is one of the greatest threats to global health of our time. A total of 2,3% of all antibiotics prescribed to women in Sweden are used to treat bacterial vaginosis.*
*) Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2024